We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

TAIGEN BIOSCIENCE CORP

Taigen Bioscience Corporation develops, manufactures, and sells nucleic acid extraction reagents, fully automated ins... read more Featured Products: More products

Download Mobile App




Commercial Molecular Assay Validated for Dengue Virus Outbreak

By LabMedica International staff writers
Posted on 28 Oct 2016
Dengue virus (DENV) is a member of the viral genus Flavivirus (family Flaviviridae) that is transmitted by mosquitos, causing endemic and epidemic outbreaks in tropical and subtropical areas.

Accurate, rapid, and early diagnosis of DENV infections is important for public health and optimal clinical care; however, the gold standard method of cell culture-dependent isolation of DENV during the acute phase of infection is time-consuming and cumbersome.

Medical scientists at the National Cheng Kung University (Tainan, Taiwan) collected serum samples from patients with suspected DENV infection between July and November 2015. More...
Sera from patients with suspected DENV infection were screened using the one-step immunochromatographic SD BIOLINE Dengue DuoDengue NS1 Ag + Ab Combo assay. This rapid assay contains two test devices, which can simultaneously detect the levels of nonstructural protein 1(NS1) antigen, and immunoglobulin M (IgM) and IgG in a sample, respectively, within 15 minutes.

Viral ribonucleic acid (RNA) was extracted from serum samples and an extraction control sample using a QAIamp viral RNA mini kit or the automated extraction system LabTurbo Virus mini Kit in LabTurbo 48 Compact System. Quantitative real-time polymerase chain reaction (qRT-PCR) analysis of viral loads was performed using LightMix dengue virus EC kit, which is capable of identifying all four dengue serotypes.

A total of 8,989, 8,954, and 1,581 samples were subjected to NS1 antigen detection, IgM and IgG detection, and LightMix assays, respectively. The LightMix assay yielded a linear curve for viral loads (VL) between 102 and 106 copies/reaction, and the minimum detection limits for DENV serotype 1 (DENV1) and DENV2, DENV3, and DENV4 were 1, 10, and 100 focus forming units (FFU)/mL, respectively. There was 88.9% concordance between the results obtained using the NS1 antigen combo kit and by LightMix analysis, and the diagnostic sensitivity and specificity of the two methods were 89.4% and 100%, and 84.7% and 100%, respectively.

The authors concluded that the LightMix assay was effective for early diagnosis of DENV infection. The data indicated that high viral loads during primary infection in elderly patients may be a positive predictor for severe illness, and may contribute to high mortality rates. The study was published on October 12, 2016, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
National Cheng Kung University



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.